Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Fulcrum Therapeutics (FULC) Return on Capital Employed (2019 - 2026)

Fulcrum Therapeutics (FULC) has 8 years of Return on Capital Employed data on record, last reported at 24.97% in Q1 2026.

  • On a quarterly basis, Return on Capital Employed fell 1985.0% to 24.97% in Q1 2026 year-over-year; TTM through Mar 2026 was 24.97%, a 1985.0% decrease, with the full-year FY2025 number at 28.21%, down 1939.0% from a year prior.
  • Return on Capital Employed reached 24.97% in Q1 2026 per FULC's latest filing, up from 30.54% in the prior quarter.
  • Over the last five years, Return on Capital Employed for FULC hit a ceiling of 5.12% in Q1 2025 and a floor of 56.33% in Q2 2022.
  • A 5-year average of 34.37% and a median of 38.77% in 2025 define the central range for Return on Capital Employed.
  • On a YoY basis, Return on Capital Employed climbed as much as 4289bps in 2025 and fell as far as -2758bps in 2025.
  • Tracing FULC's Return on Capital Employed over 5 years: stood at 51.04% in 2022, then increased by 15bps to 43.46% in 2023, then skyrocketed by 81bps to 8.46% in 2024, then crashed by -261bps to 30.54% in 2025, then rose by 18bps to 24.97% in 2026.
  • Business Quant data shows Return on Capital Employed for FULC at 24.97% in Q1 2026, 30.54% in Q4 2025, and 38.77% in Q3 2025.